The Procter & Gamble Company, Cincinnati, OH, United States.
Toxicology. 2010 May 27;271(3):87-93. doi: 10.1016/j.tox.2010.03.007. Epub 2010 Mar 17.
Microbial enzymes have been used in laundry detergent products for several decades. These enzymes have also long been known to have the potential to give rise to occupational type 1 allergic responses. A few cases of allergy among consumers using dusty enzyme detergents were reported in the early 1970s. Encapsulation of the enzymes along with other formula changes were made to ensure that consumer exposure levels were sufficiently low that the likelihood of either the induction of IgE antibody (sensitization) or the elicitation of clinical symptoms be highly improbable. Understanding the consumer exposure to enzymes which are used in laundry and cleaning products is a key step to the risk management process. Validation of the risk assessment conclusions and the risk management process only comes with practical experience and evidence from the marketplace. In the present work, clinical data from a range of sources collected over the past 40 years have been analysed. These include data from peer reviewed literature and enzyme specific IgE antibody test results in detergent manufacturers' employees and from clinical study subjects. In total, enzyme specific IgE antibody data were available on 15,765 individuals. There were 37 individuals with IgE antibody. The majority of these cases were from the 1970s where 23 of 4687 subjects (0.49%) were IgE positive and 15 of the 23 were reported to have symptoms of allergy. The remaining 14 cases were identified post-1977 for a prevalence of 0.126% (14/11,078). No symptoms were reported and no relationship to exposure to laundry and cleaning products was found. There was a significant difference between the pre- and post-1977 cohorts in that the higher rates of sensitization with symptoms were associated with higher exposure to enzyme. The clinical testing revealed that the prevalence of enzyme specific IgE in the population is very rare (0.126% since 1977). This demonstrates that exposure to these strong respiratory allergens via use of laundry and cleaning products does not lead to the development of sensitization and disease. These data confirm that the risk to consumers has been properly assessed and managed and support the concept that thresholds of exposure exist for respiratory allergy. Expansion of enzyme use into new consumer product categories should follow completion of robust risk assessments in order to continue ensuring the safe use of enzymes among consumers.
几十年来,微生物酶已被用于洗衣洗涤剂产品中。这些酶也早就被认为有引发职业 1 型过敏反应的潜力。在 20 世纪 70 年代早期,有报道称一些使用灰尘酶洗涤剂的消费者出现过敏反应。为了确保消费者暴露水平足够低,从而使 IgE 抗体诱导(致敏)或临床症状发生的可能性极低,对酶进行了封装,并对其他配方进行了更改。了解在洗衣和清洁产品中使用的酶对消费者的暴露情况是风险管理过程的关键步骤。只有通过市场的实际经验和证据,才能验证风险评估结论和风险管理过程。在本工作中,分析了过去 40 年来从各种来源收集的临床数据。这些数据包括同行评议文献中的数据以及洗涤剂制造商员工和临床研究对象的酶特异性 IgE 抗体检测结果。总共,可获得 15765 个人的酶特异性 IgE 抗体数据。有 37 个人具有 IgE 抗体。这些病例大多数来自 20 世纪 70 年代,其中 4687 名受试者中有 23 名(0.49%)IgE 阳性,其中 15 名报告有过敏症状。其余 14 例是在 1977 年后发现的,患病率为 0.126%(14/11078)。没有报告症状,也没有发现与接触洗衣和清洁产品之间的关系。1977 年前后的队列之间存在显著差异,即症状相关的致敏率较高与更高的酶暴露率有关。临床检测显示,人群中酶特异性 IgE 的患病率非常罕见(自 1977 年以来为 0.126%)。这表明通过使用洗衣和清洁产品接触这些强烈的呼吸道过敏原不会导致致敏和疾病的发展。这些数据证实,已经对消费者的风险进行了适当的评估和管理,并支持存在呼吸道过敏暴露阈值的概念。为了继续确保消费者安全使用酶,应在完成稳健的风险评估后,将酶的使用扩展到新的消费产品类别中。